Modernizing Clinical Trials for Patients With Cancer.

In this Viewpoint, directors at the National Cancer Institute (NCI) review reforms to the NCI clinical trials program, including use of historical controls and aggregating data from existing trials to improve trial efficiency, focusing on rare cancers that industry may overlook, enrolling patients based on molecular alterations instead of disease type, and establishing research facilities in underserved communities. [ABSTRACT FROM AUTHOR]